Oral Antiviral Xofluza Reduces Flu Transmission in Households
A phase III study demonstrated that a single oral dose of Xofluza significantly reduced the spread of influenza within households.
Tag: baloxavir marboxil Xofluza
Oral Antiviral Xofluza Reduces Flu Transmission in Households
A phase III study demonstrated that a single oral dose of Xofluza significantly reduced the spread of influenza within households.
Read More
FDA Expands Xofluza Approval Approval for Post-exposure Prevention
The FDA expanded the approved indication for Genetech’s Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza for patients 12 years of age and older after contact with an individual who has the flu.
Read More
Xofluza Expanded to High-risk Flu Patients
The US FDA has approved a supplemental New Drug Application for Xofluza to treat flu in patients 12 and older who are at high risk of developing flu-related complications.
Read MoreRoche’s Xofluza Shows Benefits for High-risk Flu Patients
Roche’s investigational single-dose antiviral Xofluza showed superior efficacy in speeding up improvement of flu symptoms in people at high risk of complications.
Read More